source
- Researchers suspect Exelixis used a minor tweak to cabozantinib to sidestep patent cliffExelixis' 2025 financial results highlighted the importance of its drug cabozantinib, which has been a major revenue source for the company. A group of analysts argue that the company introduced a…
- Infinimmune secures $75 million Series A to develop longer-lasting eczema antibody therapiesInfinimmune, a biotech based in Alameda, California, announced on Tuesday that it has closed a $75 million Series A financing round. The capital will support the development of its first two clinic…